The Trinity: Interplay among Cancer Cells, Fibroblasts, and Immune Cells in Pancreatic Cancer and Implication of CD8\textsuperscript{+} T Cell-Oriented Therapy

Yu-Hsuan Hung\textsuperscript{1}, Li-Tzong Chen\textsuperscript{1,2,3,*} and Wen-Chun Hung\textsuperscript{1,*}

Abstract: The microenvironment in tumors is complicated and is constituted by different cell types and stromal proteins. Among the cell types, the abundance of cancer cells, fibroblasts, and immune cells is high and these cells work as the “Trinity” in promoting tumorigenesis. Although unidirectional or bidirectional crosstalk between two independent cell types has been well characterized, the multi-directional interplays between cancer cells, fibroblasts, and immune cells in vitro and in vivo are still unclear. We summarize recent studies in addressing the interaction of the “Trinity” members in the tumor microenvironment and propose a functional network for how these members communicate with each other. In addition, we discuss the underlying mechanisms mediating the interplay. Moreover, correlations of the alterations in the distribution and functionality of cancer cells, fibroblasts, and immune cells under different circumstances are reviewed. Finally, we point out the future application of CD8\textsuperscript{+} T cell-oriented therapy in the treatment of pancreatic cancer.

Keywords: pancreatic cancer; fibroblasts; immunity; CD8\textsuperscript{+} T cells

1. Introduction

Pancreatic cancer is a deadly malignancy around the world according to the latest global reports\textsuperscript{[1,2]} and is expected to be the second leading cause of cancer-related death in 2030\textsuperscript{[2]}. Surgery\textsuperscript{[3]}, radiotherapy\textsuperscript{[4]}, chemotherapy\textsuperscript{[5,6]}, and immunotherapy\textsuperscript{[7,8]} are available for pancreatic cancer treatment; however, recurrence and metastasis occur\textsuperscript{[9–15]} frequently after treatment\textsuperscript{[16]}. Therefore, the identification of additional molecular targets and development of novel therapeutic strategies are urgently needed. Pancreatic cancer cells exhibit multiple dysregulations in oncogenes\textsuperscript{[17–19]} and tumor suppressor genes\textsuperscript{[18,20–22]} to enhance tumor initiation, promotion, and progression. While corresponding targeted therapies work well in some cancer types\textsuperscript{[23–27]}, the fibrotic nature of pancreatic cancer makes it hard for drugs to access\textsuperscript{[28,29]}. This property and the immunologically “cold” tumor microenvironment\textsuperscript{[30,31]} render immunotherapy as rarely effective\textsuperscript{[7,8,32]}. Overcoming these barriers may provide a new direction for the design of targeted therapy\textsuperscript{[33–35]}. In the pancreatic tumor microenvironment, fibroblasts and immune cells call for the attention of researchers due to their abundance\textsuperscript{[35,36]} and functional diversity\textsuperscript{[33,34]}, which we introduce below.

2. Fibroblasts and Immune Cells in Pancreatic Cancer

2.1. Fibroblast

Fibroblasts in pancreatic cancer can be divided into not only quiescent/activated statuses but also different subtypes, with the latter based on single cell RNA sequencing...
on patient specimens [37]. The quiescent status of fibroblasts in pancreatic cancer is transformed by external signals [38], leading to morphological change as well as factor secretion such as cytokines, chemokines, and extracellular components [38,39]. The subtype differences in fibroblasts around the pancreas exist before tumor formation [40]. When pancreatic pre-cancerous lesions develop, the fibroblasts surrounding them may receive differential clues due to spatial distribution [35,36,41–44] and give rise to different phenotypes such as myofibroblast-like, inflammatory, and antigen-presenting. The subtype classifications are further supported by single cell RNA sequencing on mouse pancreatic tumors [45,46]. In three independent single cell RNA sequencing studies [37,45,46], the myofibroblast-like subtype and inflammatory subtype existed in pancreatic bulky tumors, responded to diverse signals, and modulated disease progression differentially. As these subtypes are interchangeable [43,46] and have different prognostic impacts [47], targeting fibroblasts in pancreatic cancer should be considered carefully [35,36,41,42,48–51], especially with the previous in vivo findings that fibroblast depletion in pancreatic cancer speeded up cancer metastasis [52,53].

Myofibrotic cancer-associated fibroblasts (myCAFs) and inflammatory CAFs (iCAFs) are frequently identified in pancreatic cancer [43,45,46,54,55] and other cancer types [56–60]. In spontaneous pancreatic cancer mouse models, myCAFs and iCAFs exhibit different genetic profiles and oncogenic activities [49]. A myCAF functions in ECM remodeling, expresses α-SMA, localizes near cancer cells, and responds to transforming growth factor β (TGFβ) [36,49,60–66]. An iCAF acts in factor secretion, expresses interleukin-6 (IL6), localizes distantly from tumor, and responds to IL1 [49,60,62–66]. While an iCAF is tumor-promoting, the comprehensive influence of a myCAF on pancreatic cancer development is still under debate [49,62,65]. What makes CAFs in pancreatic cancer more complicated is their interchangeability [36].

As well as the main CAF subtypes, including myCAF and iCAF, CAF heterogenicity is another important issue in pancreatic cancer development. This heterogenicity starts from the origins of CAFs, which may be resident fibroblasts, pancreatic stellate cells, adipocytes, pericytes, endothelial cells, and mesenchymal stem cells. In terms of subtype heterogenicity, the antigen-presenting CAF (apCAF) [38,67,68] is also present. Common markers for a myCAF include α-SMA [38,40,67] and transgelin [38,40]. For an iCAF, these markers are IL6 [38,40,67] and CXCL12 [38,40]. For the apCAF, the markers are MHCII [40,68] and Saa3 [38,40]. The myCAF in pancreatic cancer associates with increased ECM deposition [69], decreased T cell infiltration [67,68], and altered tumor development [67–69]. The iCAF links to increased pancreatic cancer stemness [67], drug resistance [67], tumorigenesis [68,69], and immunosuppression [68,69]. The apCAF mostly associates with antigen presentation [68,69].

2.2. Immune Cell

The immune cell is another critical component in the pancreatic cancer microenvironment [29,33,70–77]; though, with its immunologically cold nature partially attributed to desmoplasia, pancreatic cancer patients with CD8⁺ lymphocyte infiltration have a better prognosis [78,79]. For other lymphoid cells, the role of CD4⁺ lymphocytes in pancreatic cancer heavily depends on the helper cell type. The existence of FoxP3⁺ regulatory T lymphocytes (Treg) are associated with a higher risk for pancreatic cancer [78]. Conversely, the amount of B lymphocytes predicts better pancreatic cancer prognosis [78,79]. The presence of nature killer (NK) cells also benefits patient survival [70] as long as their cytotoxicity is retained [70,77,79]. In myeloid cells, mast cells associate with pancreatic cancer growth and angiogenesis [80–82]. A higher ratio of neutrophils/lymphocytes links to a poor clinical outcome of pancreatic cancer patients in meta-analyses [83,84]. On the contrary, macrophages affect pancreatic cancer cell behaviors in a polarization-dependent manner. M2 macrophages, with anti-inflammatory property, frequently block immune surveillance and promote cancer growth. In contrast, M1 macrophages with pro-inflammatory character elicit immunity to fight against tumor. However, dissection of tumor-associated
Biomedicines 2022, 10, 926

3 of 19

macrophages (TAM) in pancreatic cancer revealed that these macrophages may display features of both polarization types. These phenomena were widely observed and reviewed in detail [34,71,73,76,79,85]. While the mechanism by which dendritic cells influence pancreatic tumors is still unclear, its potential anticancer efficiency via vaccination has been observed for a long time [86–91] and has been recently revisited [92–94].

In addition to the M2 macrophage, myeloid-derived suppressor cells (MDSC) play an important role in pancreatic tumorigenesis [95]. These suppressor cells include monocytic (M-MDSC) and polymorphonuclear cells (PMN-MDSC). They arise from the impaired differentiation of myeloid progenitor cells during myelopoiesis, and this impairment is commonly observed during tumorigenesis [96]. For M-MDSC, Trovato et al. found both M-MDSC and PMN-MDSC in pancreatic cancer tissues, negatively correlated with T cell population [97]. In the peripheral blood mononuclear cell (PBMC) subset, M-MDSC percentage was higher in pancreatic cancer patients than in healthy donors. Using whole blood samples in the validation cohort, the authors found CD14+ M-MDSC still displayed greater suppression on T cell proliferation than CD66b+ PMN-MDSC did. This resulted from STAT3 activation and subsequent arginase expression, and could be counteracted by arginase inhibition. For PMN-MDSC, Peng et al. reported that, in an H7 orthotopic pancreatic cancer mouse model, apolipoprotein A-I mimetic peptide L-4F decreased tumorigenesis via PMN-MDSC suppression [98]. Increments in CD8+ T cells and IFNγ in the tumor and spleen after L-4F treatment were observed, compared to a control Sc-4F treatment group. Mechanistically, this suppression was achieved by inhibitions of ROS production and STAT3 phosphorylation. Conversely, Kramer et al. showed that PMN-MDSC in pancreatic cancer was associated with the increased expression of Wnt inhibitor Dickkopf-1 (Dkk1) [99].

3. Mechanisms Underlying the Interplay among Pancreatic Cancer Cells, Fibroblasts, and Immune Cells

3.1. Cytokine and Chemokine

What makes the situation even more complicated is the interplay among pancreatic cancer cells, fibroblasts, and immune cells. A change in one component affects the whole picture in a pancreatic tumor [33–36,48,50,51,70,73–75,77,100]. Mechanistically, cytokines and chemokines secreted from pancreatic cancer cells, fibroblasts, or immune cells modulate the behaviors of the other two populations [35,36,49]. However, only limited targets have been identified in these multi-directional interplays [101] (Table 1 and Figure 1). Mucciolo et al. utilized knockout mice and antibody treatment to explore the role of IL17 in the pancreatic tumor microenvironment and found the loss of this cytokine modulated extracellular matrix (ECM) composition and increased CD3+ cell infiltration [101]. In pancreatic cancer cells, mutant Kras elicited IL17 expression [101,102], possibly via the STAT3 signaling pathway [101,105]. IL17, in turn, worked on fibroblasts to reshape the ECM [101,105] and on immune cells to block their antitumor function [106–108]. With a similar approach, Zhang et al. revealed that regulatory T cells’ (Treg) depletion in a transgenic pancreatic cancer mouse model surprisingly accelerated pancreatic tumorigenesis via inactivation of the PDGFRβ+ SMA+ myofibroblast [109]. In addition, compensation by other pro-tumor myeloid-derived suppressor cells (MDSC) was observed once Treg were depleted. The results of RNA sequencing pointed out that in this process, many C-C chemokine receptor type 1 (CCR1) ligands were upregulated, and CCR1 inhibition retarded pancreatic tumorigenesis, resulting from Treg depletion. In terms of fibroblasts, Feig et al. showed that fibroblast activation of protein-positive (FAP)+ cancer-associated fibroblasts (CAFs) participated in pancreatic cancer formation, and the depletion of FAP+ fibroblasts in a transgenic pancreatic cancer mouse model decreased tumor development [110]. This might be through C-X-C motif chemokine ligand 12 (CXCL12) expression in FAP+ fibroblasts and its effect on T cell exclusion, specifically via high mobility group box 1 (HMGB1) [111,112]. Accordingly, loss of the CD4/CD8 cells reversed the effect of FAP+ fibroblast depletion on
tumor growth. In addition, the inhibition of CXCR4, the cognate receptor for CXCL12, by AMD3100 improved anti-PD-L1 efficiency.

**Table 1.** Mechanisms underlying the interplay among pancreatic cancer cells, fibroblasts, and immune cells.

| Molecule       | Cell Type | Mechanism                                                                 | Reference |
|----------------|-----------|----------------------------------------------------------------------------|-----------|
| TGFβ           | T<sub>reg</sub> | TGFβ from T<sub>reg</sub> activates SMA<sup>+</sup> myofibroblasts and their expression of CCR1 ligands to recruit MDSC | [109]     |
| CXCL12         | CAF       | CXCL12 from FAP<sup>+</sup> CAF increases T cell exclusion and cancer growth  | [110]     |
| Type I collagen | Myofibroblast | Type I collagen from myofibroblast decreases SOX9 expression and subsequently increases CXCL5 in PDAC to recruit MDSC | [113]     |
| ROS            | CAF       | ROS from CAF increases monocyte differentiation into M2 macrophages and their production of M-CSF to increase the invasiveness of PDAC | [114]     |

**Figure 1.** Mechanisms underlying the interplay among pancreatic cancer cells, fibroblasts, and immune cells. (A) Collagen I around fibroblasts (brown) stimulates pancreatic cancer cells (red) and increases the Rho/SOX9 activation, which leads to CXCL5 expression to activate myeloid cells (purple). Myeloid cells, in turn, express arginase 1 to suppress CD8<sup>+</sup> T cell (green). (B) Fibroblasts (brown) modulate macrophage (purple) polarization and function via ROS, and M2 polarized macrophages assist the proliferation of pancreatic cancer cell (red) via macrophage colony-stimulating factor (M-CSF).
3.2. Extracellular Signal

In addition to cytokines and chemokines, molecules such as extracellular components and stress signals also participate [113,114] in the interaction among the “Trinity”. Chen et al. demonstrated that the loss of collagen I in α-SMA+ fibroblasts enhanced pancreatic cancer progression via CXCL5 upregulation in cancer cells and the subsequent activation of MDSC [113]. As CXCL5 is one of the most upregulated factors in a pancreatic cancer mouse model with collagen I knockout, the authors proposed that this ECM alteration stimulated SOX9 transcription activation [113,115] in cancer cells [113]. CXCL5 then recruited and polarized MDSC into a pro-tumor type to enhance the growth of pancreatic cancer cells. Furthermore, MDSC suppressed functions of T and B cells via arginine depletion. These effects on ECM alteration and immune suppression via cancer cells and MDSC emphasized the importance of α-SMA+ fibroblasts in pancreatic tumorigenesis by affecting collagen deposition. In terms of stress signals, Zhang et al. established primary cultures of fibroblasts from human pancreatic cancer tissues, and found they affected monocytes in a reactive oxygen species (ROS)-dependent manner [114]. With either a CAF-conditioned medium or direct CAF co-culture, monocytes displayed increased M2 polarization. This phenomenon was associated with upregulated ROS production in monocytes, and both ROS amount and M2 polarization were inhibited by antioxidants. CAFs increased ROS in monocytes via M-CSF, which is specific to cancer-associated fibroblasts as normal fibroblasts rarely produce this factor. Moreover, the CAF-stimulated monocytes are capable of inducing Stat3 and Akt phosphorylation in pancreatic cancer cells and subsequently increasing their growth. Pancreatic cancer cells also express a variety of factors including VEGF [116] to activate Stat3 and Akt [117,118], and subsequently modulate macrophage behavior. This study suggests the complex interaction among cancer cells, fibroblasts, and immune cells during pancreatic cancer development.

3.3. Pathway Modulation

Researchers also utilized additional approaches to dissect the interplay among the “Trinity” members in pancreatic tumors, such as inhibitor treatment and gene delivery. Zhao et al. applied M-CPA/PTX, a polymeric micelle-based nanof ormulation of sonic hedgehog inhibitor (cyclopamine, CPA) and paclitaxel (PTX), to modulate stroma in pancreatic cancer [119]. M-CPA/PTX increased intratumoral vasculature density to benefit CD8+ T cell infiltration without altering the ECM and fibroblasts. In the bulky tumor, VEGFR2 and Shh phosphorylations were suppressed by M-CPA/PTX. Moreover, M-CPA/PTX improved anti-PD-1 efficiency via IFN-γ from CD8+ T cells. Zhou et al. directly applied gene delivery targeting relaxin to hamper fibrosis in cancers [120]. Relaxin is an insulin-like peptide hormone with diverse biological functions but is known for fibrosis resolution therapeutically [120,121]. The authors utilized this advantage to test its effect on pancreatic desmoplasia by targeting macrophages as they express the relaxin receptor (relaxin family peptide receptor type 1, RXFP1). They found that local relaxin plasmid (pRLN) delivery in the format of aminoethyl anisamide (AEAA)-conjugated lipid-protamine-DNA (LPD) nanoparticle induced macrophage recruitment [121]. These macrophages uptook relaxin and activated themselves to express cytokines and enzymes for fibrosis depletion. This phenomenon is accompanied with (1) a decrease in α-SMA+ fibroblasts; (2) a reduction in collagen I; (3) an increase in antitumor CD8+ T and NK cells; (4) attenuation in pro-tumor Trg. Furthermore, pRLN benefited anti-PD-L1 efficiency, even though pRLN itself already displayed a better treatment effect in vivo. Although the advantage of stroma targeting in pancreatic cancer is still under debate [52,53], the works from Zhao et al. [119] and Zhou et al. [120] supported the notion that the entry of CD8+ T cells has a higher benefit than the
depletion of fibroblasts in this process, as CD8+ T cell infiltration is the main determinant of treatment efficiency with or without fibroblast alteration.

4. Correlation of Alterations in the “Trinity” Population in Preclinical Model and Clinical Setting

In addition to discussing the mechanisms of the multi-functional interplay between cancer cells, fibroblasts, and immune cells, we also summarized the correlation of alterations of the “Trinity” members under different circumstances (Table 2). Pancreatic tumor tissues showed increased focal adhesion kinase (FAK) activation and ECM accumulation. Jiang et al. reported that the FAK inhibitor accordingly reversed ECM alteration and suppressed tumorigenesis in animals. The authors demonstrated that MDSC infiltration was suppressed by the FAK inhibitor. In this preclinical model, co-reduction in fibroblasts and MDSCs was found after FAK inhibition, suggesting a role of FAK in controlling the population of these two cell types in pancreatic cancer [122].

Gorchs et al. isolated fibroblasts from human pancreatic tumors and found that CAFs expressed more PD-L1 and PD-L2 compared to normal skin fibroblast [123]. The co-culture of CAFs resulted in the suppression of T cell proliferation in a prostaglandin E2 (PGE2)-dependent manner. Consequently, PGE2 inhibition by the COX2 inhibitor restored this phenotypic change. For those T cells still proliferating, CAFs also hindered their function by (1) increasing co-inhibitory molecules and (2) decreasing functionality, suggesting the antagonism of cell number and biological activity between fibroblasts and T cells.

Ireland et al. showed stromal Gas6 inhibition by neutralizing antibody suppressed metastasis in a spontaneous pancreatic cancer mouse model [124]. To find the origin of Gas6 secretion, the authors used a cell sorting approach and confirmed macrophages and fibroblasts were the main Gas6 producers. Additionally, immunohistochemical (IHC) staining on serial sections further verified the activation of downstream AXL signaling [125,126]. A Gas6 blockade decreased the epithelial–mesenchymal transition (EMT) in pancreatic cancer cells, while neither myeloid cells nor T cells were affected. However, Gas6 inhibition reduced NK cell recruitment. These results suggest that fibroblasts and macrophages modulated cancer cells in a unidirectional way via Gas6.

Table 2. Correlation of the alterations in cancer cells, fibroblasts, and immune cells in co-culture, animal models, and clinical samples.

| Molecule | Cell Type | Association | Reference |
|----------|-----------|-------------|-----------|
| NA       | PDAC      | Collagen/fibroblast ↓ post FAKi treatment | [122]     |
|          |           | Macrophage ↓ post FAKi treatment         |           |
|          |           | G-MDSC ↓ post FAKi treatment             |           |
| NA       | PDAC      | CAF PD-L1/PD-L2↑ | [123]     |
|          |           | CD4/CD8 proliferation ↓ |           |
|          |           | CD4/CD8 co-inhibitory marker↑ |           |
|          |           | CD8 function ↓ |           |
| NA       | PDAC      | Vimentin ↓ post α-Gas6 treatment | [124]     |
|          |           | NK ↓ post α-Gas6 treatment |           |
| NA       | PDAC      | Collagen Density not altered | [127]     |
|          |           | T cell Infiltration not altered |           |
| CDK2/4/6 | PDAC      | CAF Co-occurrence ↑ | [128]     |
| STAT3    | PDAC      | CAF Co-occurrence ↑ |           |
|          |           | Immunity Onco-immune signature ↑ |           |
The correlation of the ECM and immune cells in clinical samples has also been investigated. Kamionka et al. showed the collagen composition in pancreatic tumor tissues was not significantly linked with immune cell infiltration, suggesting collagen organization has a minor impact on T cell distribution [127].

To understand the associations of different cell types in the tumor microenvironment, Lawal et al. applied databases to analyze multi-omics results of multiple cancers emphasizing the STAT3/CDK2/4/6 axis [128]. As this axis is highly expressed across various cancer types, the authors correlated it to epigenetics and immunity, and found an association between CAFs and STAT3 in pancreatic cancer. With a similar high-throughput concept, MacNeil et al. surveyed the prognostic impact of CAFs and tumor-infiltrating lymphocytes (TIL) in pancreatic cancer patients [129]. Multivariate analysis showed that CD8⁺ T cells of TIL and FAP⁺ CAF are predictors of survival; the former predicted better survival, while the latter correlated with worse survival. On the other hand, Tahkola et al. directly analyzed the effect of hyaluronan accumulation on pancreatic cancer immune cell infiltration, and found the infiltration was significantly interrupted by hyaluronan as reflected by a low immune cell score across survival types (overall and disease-specific) via univariate and multivariate analyses [130]. Moreover, Nizri et al. studied pancreatic cancer lymph node (LN) metastasis and analyzed its association to desmoplasia and the ECM profile. They found collagen, TGFβ (fibroblast-related), and GATA3 ((Th2) immunity-related) are expressed mainly in desmoplasia-high LN [131]. A similar association in pancreatic cancer was also observed in the study by Sadozai et al. [132]. The authors analyzed the components in the pancreatic tumor microenvironment by IHC staining and RNA sequencing to compare the differences in long-term and short-term survivors. The results from both studies revealed that (1) a long-term survivor has less α-SMA and (2) a long-term survivor has more CD3⁺ T cells in the tumor and stroma parts. State-of-the-art technology such as single cell RNA sequencing accelerates target/solution identification in cancer research.

### Table 2. Cont.

| Molecule | Cell Type | Association | Reference |
|----------|-----------|-------------|-----------|
| NA       | PDAC      | CD4         | Disease progression ↓ |
|          |           | CD8         | Disease progression ↓ |
|          |           | Thy-1⁺ CAF  | Disease progression ↓ |
|          |           | FAP⁺ CAF    | Disease progression ↑ |
| Stromal hyaluronan accumulation | NA | CD8/CD3-based immune cell score | ↓ |
|          | PDAC      | Desmoplasia | COL11A1/COL11A2/COL1A1/TGF-β mRNA ↑ |
|          | PDAC      | α-SMA/fibrosis | ↑ in STS |
|          | PDAC      | CD68/CD163  | ↑ in STS |
|          | PDAC      | CD4         | ↓ in STS |
|          | PDAC      | iNOS        | ↓ in STS |
|          | PDAC      | Foxp3       | ↑ in STS |
|          | PDAC      | B cell/DC   | ↓ in STS |
|          | PDAC      | Metabolic active CAF (meCAF) | ↑ in dense (high desmoplasia) group |
|          | PDAC      | CD8         | ↑ in loose (low desmoplasia) group |
|          | PDAC      | Response to α-PD-1 | ↑ in loose group |

FAK, focal adhesion kinase; STS, short-term survivors; ↑, increment; ↓, decrement.
and with this approach, Wang et al. identified the CAF subtype with a highly activated metabolic state (meCAF) in pancreatic cancer patients with loose stroma (low desmoplasia) [55]. Under this circumstance, CD8+ T cells are more abundant in both single cell RNA sequencing and IHC analysis. While the meCAF predicted worse survival, it displayed a better response toward anti-PD-1. This work suggested the identification and potential application of a novel fibroblast subtype for pancreatic cancer research and therapy. Collectively, the aforementioned studies conclude that the alterations in the “Trinity” members in pancreatic tumors provide useful information in predicting a patient’s clinical outcome and in providing a therapeutic strategy.

5. Treating Pancreatic Cancer with CD8+ T Cell-Orientated Approach

5.1. Preclinical Study

Treating pancreatic cancer by directly increasing CD8+ T cell infiltration and/or function is a new idea with clinical merit (Figure 2). Mace et al. found that an IL6 blockade improved anti-PD-L1 efficiency and retarded pancreatic tumorigenesis [133]. With the IL6 expression by pancreatic stellate cell (PSC) in mind, the authors tested the effect of an IL6 neutralizing antibody on subcutaneous tumors of MT5 and Panc02 (mouse pancreatic cancer cell lines), and demonstrated that while IL6 antibody itself had a minor effect, its combination benefited anti-PD-L1 efficiency. This is correlated to increased effector CD8+ T cell infiltration in the tumors. On the other hand, only CD8+ cell neutralization, but not CD4+ cell neutralization, blunted the antitumor effect that resulted from the IL6 blockade. In an orthotopic model, treatment of the IL6 antibody could not prevent CD3+ cell recruitment. Principe et al. demonstrated that TGFβ is of equal importance in this kind of treatment, as KC mouse (P48-Cre × LSL-KRASG12D) receiving wild-type CD8+ T cell still displayed disease progression, but tumor growth was ceased when the CD8+ T cells harvested from Tgfbr1−/− mice were injected [134]. Consistent with this finding, TGFβ inhibitor galunisertib also showed the same inhibitory effect in the animal model and displayed better efficiency when combined with anti-PD-1 antibody. While CD8+ T cell infiltration was not increased, its functions regarding memory subset and IFNγ/perforin expression were all boosted. In addition to IL6 and TGFβ, CXCR4-mediated signaling also affects pancreatic cancer treatment significantly. Two studies addressed the importance of CXCR4 in pancreatic tumorigenesis [135,136]. Seo et al. applied patient specimens to investigate the influence of CXCR4 inhibitor AMD3100 on apoptosis, and found it did so by redistributing the CD8+ T cells to the juxtatumoral stroma with the potential release of granzyme B and IFNγ. In the COMBAT clinical trial, Bockorny et al. applied another CXCR4 antagonist, BL-8040, to test its antitumor effect together with pembrolizumab for pancreatic cancer patients. Patients receiving combinatory therapy displayed increased CD8+ T cell mobilization, especially that of cytotoxic (granzyme B+) CD8+ T cells. When further combined with chemotherapy, most patients displayed a better response compared to their own baselines.

In addition to cytokine/chemokine, the direct activation of CD8+ T cells by membrane proteins is also implicated in pancreatic cancer treatment. Audenaerde et al. and Panni et al. investigated the role of CD40 agonist/IL15 and CD11b agonist, respectively, for this purpose [137,138]. Audenaerde et al. injected mouse cancer cells subcutaneously and tested the effect of different molecules on tumor growth. They found that CD40 agonist/IL15 is the most effective for suppressing tumor growth. This was achieved by the CD8+ T cell as its depletion reversed the therapeutic effect. Accompanying this phenomenon, antitumor factors and effector/memory subsets were all increased. Moreover, the suppressive effect of CD40 agonist/IL15 could still be observed in re-challenge experiments after a 100-day tumor-free period. Panni et al., alternatively, utilized CD11b agonist ADH-503 on an orthotopic mouse model and demonstrated this agonist promoted the recruitment of immune cells including cytotoxic and memory CD8+ T cells under rapid proliferation and activated their antitumor functions. Mechanistically, ADH-503 acted through a conventional dendritic cell (cDC) to achieve tumor suppression, as demonstrated by the lack of response.
to ADH-503 in a cDC-lacking Batf3−/− mouse. Impressively, the CD11b agonist itself displayed significant efficiency in pancreatic cancer treatment as a sole agent in both subcutaneous and orthotopic models. More importantly, ADH-503 combined with chemotherapy and immunotherapy to dramatically inhibit tumor growth. Modulation of the immune microenvironment is equally important. Michaelis et al. demonstrated that TLR7/8 agonist R848 prolonged survival in intraperitoneal and orthotopic mouse models of pancreatic cancer [139]. R848 itself has been shown to decrease tumor mass via modulations on the immune microenvironment and cachexia.

![Diagram](https://via.placeholder.com/150)

**Figure 2.** Treating pancreatic cancer with CD8+ T cell-orientated approaches. Potential CD8+ T cell-orientated treatments for pancreatic cancer were reviewed and blockade of IL6/TGFβ/CXCR4/STAT and activation of CD40/IL15/CD11b were proposed to be effective in pancreatic cancer therapy. Solid arrow represents direct effect, while dotted arrow represents indirect effect.

Finally, the questions raised are how is CD8+ T cell-oriented therapy applied to pancreatic cancer treatment and does the entry of T cells modulate other immune cells to create a favorable anticancer immunity? Ajina et al. showed that the T cell is the determinant for pancreatic cancer suppression in various mouse strains and is a critical factor affecting the recruitment of myeloid cells [140]. They applied NanoString analysis and found Stat1 in a pancreatic cancer cell was upregulated when a T cell was presented. The upregulation of Stat1, in turn, activated the myeloid cell to blunt the T cell’s antitumor effect. As a result, FDA-approved Stat inhibitor ruxolitinib further improved anti-PD-L1 efficiency in the aforementioned models, although ruxolitinib itself displayed minor efficiency. While this improvement on pancreatic cancer suppression may not solely result from myeloid cell inhibition, as it was suggested by the authors that the abundance of MDSC was not significantly decreased, this study pinpointed the importance of CD8+ T cell-orientated treatment [141].

### 5.2. Clinical Trial

In validation of the results of the preclinical studies described above, we reviewed related clinical trials in the database (https://www.clinicaltrials.gov/) (accessed on 28 February 2022). For pancreatic cancer, STAT inhibitor was applied in trials and the benefits of this agent were reported (NCT02993731) [142] (Table 3). In this randomized, open-label, multi-center, phase 3 study, the effect of napabucasin (2-acetylfuro-1,4-naphthoquinone, BBI-608), a STAT3 inhibitor, on metastatic pancreatic ductal adenocarcinoma was investigated. The effects on disease progression of 1134 patients treated with napabucasin + nab-paclitaxel or nab-paclitaxel + gemcitabine were compared. In the napabucasin + nab-paclitaxel arm, patients were given napabucasin twice daily and the other two agents weekly. In arm 2 of nab-paclitaxel + gemcitabine, patients were given nab-paclitaxel and gemcitabine with the same frequency. The primary outcome was overall survival, and the secondary outcomes were progression-free survival, overall response rate, adverse events, and quality of life. No difference in overall...
survival was found between the two groups’ 565 patients (11.43 vs. 11.73 months in arms 1 and 2, respectively. For secondary outcomes, the progression-free survival in arm 1 and 2 was 6.70 vs. 6.08 months, respectively; disease control rate was 74 vs. 76%, respectively; overall response rate in both arms was 43%; adverse events was 99.8% vs. 99.3%, respectively; quality of life score was −1.63 versus −0.57, respectively (higher score represents a higher quality of life). Although the combination of napabucasin and nab-paclitaxel does not show a better effect than nab-paclitaxel + gemcitabine, this study helps to define how this STAT3 inhibitor influences disease progression in phospho-STAT3-positive patients and its potential application in the future. Recently, the effects of napabucasin in clinical trials for multiple cancers have been updated [142–144].

Table 3. Summary of clinical trials targeting IL6, TGFβ, CXCR4, CD40, and STAT for cancer treatment.

| Clinical Trial ID     | Treatment                                   | Cancer Type               | Reference |
|-----------------------|---------------------------------------------|---------------------------|-----------|
| NCT02993731           | Napabucasin + nab-paclitaxel(+gemcitabine)  | Pancreas                  | [142]     |
| NCT00911859           | Siltuximab(+velcade-melphalan-prednisone)  | Multiple myeloma          | [145]     |
| NCT01484275           | Siltuximab                                  | Smoldering multiple myeloma| [146]     |
| NCT00906945           | G-CSF + plerixafor + mitoxantrone + etoposide + cytarabine | Acute myeloid leukemia | [147]     |
| NCT00512252           | plerixafor + mitoxantrone + etoposide + cytarabine | Acute myeloid leukemia | [148]     |
| NCT00101166           | GM.CD40L vaccination                        | Melanoma                  | [149]     |
| NCT01433172           | GM.CD40L vaccination (+CCL21)               | Lung                      | [150]     |

Napabucasin, STAT3 inhibitor; siltuximab, IL6 antibody; plerixafor, CXCR4 inhibitor.

Although the benefits of targeting IL6, TGFβ, CXCR4, and CD40 in pancreatic cancer remain elusive, clinical trials for these factors in other cancer types have shown promise. The effects of the anti-IL6 antibody in treating multiple myeloma were tested in NCT00911859 and NCT01484275 trials. In NCT00911859, this randomized, open-label, phase 2 study investigated an IL6 antibody (CNTO 328, siltuximab) and its combination with velcade-melphalan-prednisone (VMP) to treat multiple myeloma [145]. The safety of siltuximab (11 mg/kg as a 1-h intravenous infusion every 3 weeks) in patients was first confirmed in part 1 of this trial. In part 2, treatment efficiency was compared between arm A of VMP + siltuximab and arm B of VMP. The primary outcome was complete response, and secondary outcomes were overall response, duration of response, progression-free survival, overall survival, and quality of life. In arm A (52 patients) and arm B (54 patients), complete response was 26.5 and 22.4%, respectively. For secondary outcomes, in arm A and arm B, the overall response was 87.8 versus 79.6%, respectively; duration of response was 583 versus 497 days, respectively; progression-free survival was 519 versus 518 days, respectively. Conversely, the quality of life score was 8.33 and 14.78 for arm A and B, respectively. In a related publication [145], San-Miguel et al. further showed that (1) the partial response in arm A and arm B was 71 and 51%, respectively ($p = 0.0382$); (2) adverse event in arm A and arm B was 92 and 81%, respectively ($p = 0.09$). The authors concluded that there is no significant improvement in terms of complete response and outcome using siltuximab among patients with multiple myeloma. In NCT01484275, siltuximab was applied to test its safety and efficiency for patients with high-risk smoldering multiple myeloma (SMM). The safety of siltuximab in SMM patients was confirmed (15 mg/kg as a 1-h intravenous infusion every 4 weeks). This randomized, double-blind, placebo-controlled, multi-center, phase 2 trial enrolled 85 patients. The siltuximab arm (43 patients) and placebo arm (42 patients) had one-year progression-free survival rates of 84.5 and 74.4%, respectively. The time to disease progression was 125.5 versus 118 days in the siltuximab and placebo group, respectively. Therefore, siltuximab does not improve the survival of SMM patients [146].
For CXCR4, two trials (NCT00906945 and NCT00512252) studied the impact of CXCR4 blockage on disease inhibition in acute myeloid leukemia (AML). In the NCT00906945 study, the applications of G-CSF as well as CXCR4 blockade (plerixafor, AMD3100) were performed to investigate the clinical benefits. This non-randomized, open-label, phase 1/2 trial enrolled 39 patients. The results of this study showed a complete response rate of 30% and suggested the benefit of CXCR4 inhibition in AML patients [147]. In the NCT00512252 trial, without G-CSF, AMD3100 still increased the effectiveness of mitoxantrone, etoposide, and cytarabine (MEC) in AML patients. It was concluded that the CXCR4 inhibitor mobilized the AML cell to circulation and improved treatment efficiency, and plerixafor could be safely combined with chemotherapy to treat relapsed or refractory AML [148].

For membrane protein activation and its related cancer treatment, targeting CD40 was investigated in NCT00101166 and NCT01433172 trials. These trials applied a cancer vaccine that is composed of tumor cells from patient and bystander cells expressing GM-CSF and CD40L. These cells were treated with high-dose X-rays to ensure the loss of oncogenicity. This vaccine is able to better boost immunity in patients. In the NCT00101166 trial, the investigators reported that the recruitment of the CD1a+CD86+ dendritic cell could be observed in the injection site via immunohistochemistry analysis [149]. In addition, the cancer vaccine worked well for several types of solid tumors. In the NCT01433172 study, in addition to the cancer vaccine mentioned above, cytokine CCL21 was added to assist T cell recruitment and responsiveness. The results of this study revealed that GM-CSF + CD40L + CCL21 vaccination induced abundant tumor-infiltrating lymphocytes in tumors, which suggested the benefit of CD40 blockade in cancer treatment [150]. Taken together, these clinical trials shed light on the importance of IL6, TGFβ, CXCR4, and CD40 in cancer treatment, as well as their potential therapeutic effects on pancreatic cancer. Even though these clinical trials were applied to patients with cancer types other than pancreatic cancer, and the hazard ratio as well as statistical significance may be restricted due to the enrolled patient numbers, they suggest the potential application of the above treatments for pancreatic cancer patients.

5.3. Clinical Correlation

In addition to macrophages and neutrophils, the dendritic cell (DC) adds an important portion to cancer immunity via antigen presentation. The dendritic cell in pancreatic cancer also correlated with better survival [151]. Conventional DC type 1 (cDC1), type 2 (cDC2), and plasmacytoid DC (pDC) were enriched more in the stroma than in the tumor. cDC1 in the tumor stroma further predicted better disease-free survival (DFS). Mechanistically, DC function in pancreatic cancer is affected by multiple factors and proteins. Pancreatic cancer cell-derived prostaglandin E2 (PGE2) and regenerating islet-derived protein 3A (Reg3A) decreased DC function via cellular stresses and JAK2 modulation, respectively [152,153]. This subsequently led to a decrease in T cell proliferation [153]. The stromal protein also influenced DC effectiveness during pancreatic tumorigenesis as Giri et al. reported that the loss of heat shock protein 70 (Hsp70) in DC increased its functionality [154]. In terms of pancreatic cancer treatment, DC is also a critical target. Sadeghlar et al. showed that CD40L transduction in human DC increased its function and proliferation, even in the presence of a pancreatic cancer cell in co-culture [155], and Kim et al. reported that cetuximab-conjugated maleimide-polyethylene glycol-chlorin e6 induced pancreatic cancer cell death, which was accompanied by DC activation and maturation [156]. Salah et al. demonstrated that pulsed DC increased antigen-specific cytotoxic T cells among pancreatic cancer patients [157]. Recently, Kvedaraite et al. also summarized that pancreatic cancer patients had fewer DC progenitors and cDC1s, and pDC predicted better prognosis [158] (Figure 3).

Predictive signatures are essential for improvements in pancreatic cancer diagnosis and treatment. With databases including The Cancer Genome Atlas (TCGA), 2-gene TP53-associated immune prognostic model (TIPM) [159], 15-gene immune, stromal, and proliferation-associated (ISP) signature [160], 47-gene immune-related gene pairs (IRGPs) [161], 8-gene signature [162], 59-gene TMEscore-high group [163], and 5-gene module immune cluster [164],
we could predict pancreatic cancer prognosis more precisely. At protein level with tissue arrays, signatures of leukocyte subtype/stromal composition [165] also predicted differential survival among pancreatic cancer patients. Santiago et al. reviewed immunophenotypes in pancreatic cancer in great detail [166].

![Figure 3](image_url)

**Figure 3.** Scheme shows the potential effects of fibroblast on immune cell recruitment/function in pancreatic cancer. Based on the findings of recent studies, the potential effect of fibroblast on recruitment and function of CD8+ T cell, Treg, macrophage, MDSC, and DC in pancreatic cancer is proposed.

To sum up, with all the studies and reviews above, it is clear that the complex nature of the interplay between pancreatic cancer cells, fibroblasts, and immune cells is a key factor determining tumor formation and treatment response. In addition to therapies targeting fibroblasts [35,36] and immune cells [71,72], how these cells affect the rest of the bulky tumor to create a tumor-promoting microenvironment is a critical issue for continuous exploration. Both hypothesis-driven study [113,120] and high-throughput analysis [45,55] will strengthen our understanding of this important interplay guided by the cancer cells, stroma, and immunity in pancreatic cancer [140,167].

**Author Contributions:** Conceptualization, Y.-H.H. and W.-C.H.; writing—original draft preparation, Y.-H.H.; writing—review and editing, W.-C.H.; supervision, L.-T.C. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by grant CA-110-PP-17 from National Health Research Institutes, Ministry of Health and Welfare to Wen-Chun Hung.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer Statistics, 2021. *CA Cancer J. Clin.* 2021, 71, 7–33. [CrossRef] [PubMed]
2. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J. Clin.* 2021, 71, 209–249. [CrossRef] [PubMed]
3. Traub, B.; Link, K.H.; Kornmann, M. Curing pancreatic cancer. *Semin. Cancer Biol.* 2021, 76, 232–246. [CrossRef] [PubMed]
4. Yazal, T.; Bailleul, J.; Ruan, Y.; Sung, D.; Chu, F.I.; Palomera, D.; Dao, A.; Sehgal, A.; Gurunathan, V.; Aryan, L.; et al. Radiosensitizing Pancreatic Cancer via Effective Autophagy Inhibition. *Mol. Cancer Ther.* **2022**, *21*, 79–88. [CrossRef]

5. Macedo, F.I.; Ryon, E.; Maithel, S.K.; Lee, R.M.; Kooby, D.A.; Fields, R.C.; Hawkins, W.G.; Williams, G.; Maduekwe, U.; Kim, H.J.; et al. Survival Outcomes Associated with Clinical and Pathological Response Following Neoadjuvant FOLIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer. *Ann. Surg.* **2019**, *270*, 400–413. [CrossRef]

6. Yu, S.; Zhang, C.; Xie, K.P. Therapeutic resistance of pancreatic cancer: Roadmap to its reversal. *Biochim. Biophys. Acta Rev. Cancer 2021*, *1875*, 188461. [CrossRef]

7. Timmer, F.E.F.; Geboers, B.; Nieuwenhuizen, S.; Dijkstra, M.; Schouten, E.A.C.; Puijk, R.S.; de Vries, J.J.; van den Tol, M.P.; Bruynzeel, A.M.E.; Streppel, M.M.; et al. Pancreatic Cancer and Immunotherapy: A Clinical Overview. *Cancers 2021*, *13*, 4138. [CrossRef]

8. Principe, D.R.; Korc, M.; Kamath, S.D.; Munshi, H.G.; Rana, A. Trials and tribulations of pancreatic cancer immunotherapy. *Cancer Lett.* **2021**, *504*, 1–14. [CrossRef]

9. Kang, J.S.; Choi, Y.J.; Byun, Y.; Han, Y.; Kim, J.H.; Lee, J.M.; Sohn, H.J.; Kim, H.; Kwon, W.; Jang, J.Y. Radiological tumour invasion in patients with pancreatic body or tail adenocarcinoma and effect on recurrence and survival. *Br. J. Surg. 2021*, *109*, 105–113. [CrossRef]

10. Zhu, X.; Cao, Y.; Liu, W.; Ju, X.; Zhao, X.; Jiang, L.; Ye, Y.; Jin, G.; Zhang, H. Stereotactic body radiotherapy plus pembrolizumab and tramebib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: An open-label, randomised, controlled, phase 2 trial. *Lancet Oncol.* **2021**, *22*, 1093–1102. [CrossRef]

11. Chen, X.; Zhang, L.; Jiang, Y.; Song, L.; Liu, Y.; Cheng, F.; Fan, X.; Cao, A.; Gong, A.; Wang, D.; et al. Radiotherapy-induced cell death activates paracrine HMGB1-TLR2 signaling and accelerates pancreatic carcinoma metastasis. *J. Exp. Clin. Cancer Res. 2018*, *37*, 77. [CrossRef] [PubMed]

12. Zhang, L.; Shi, H.; Chen, H.; Gong, A.; Liu, Y.; Song, L.; Xu, X.; You, T.; Fan, X.; Wang, D.; et al. Dedifferentiation process driven by radiotherapy-induced HMGB1/TLR2/YAP-1 signaling enhances pancreatic cancer stemness. *Cell Death Dis.* **2019**, *10*, 724. [CrossRef] [PubMed]

13. Kawahara, K.; Takano, S.; Furukawa, K.; Takayashiki, T.; Kuboki, S.; Ohtsuka, M. The effect of the low stromal ratio induced by neoadjuvant chemotherapy on recurrence patterns in borderline resectable pancreatic ductal adenocarcinoma. *Clin. Exp. Metastasis 2022*, *39*, 311–322. [CrossRef] [PubMed]

14. Hu, Z.I.; Hellmann, M.D.; Wolchok, J.D.; Vyas, M.; Shia, J.; Stadler, Z.K.; Diaz, L.A., Jr.; O’Reilly, E.M. Acquired Resistance to Immunotherapy in MMR-D pancreatic cancer. *J. Immunother. Cancer 2018*, *6*, 127. [CrossRef]

15. Jiang, J.; Zhou, H.; Ni, C.; Hu, X.; Mou, Y.; Huang, D.; Yang, L. Immunotherapy in pancreatic cancer: New hope or mission impossible? *Cancer Lett.* **2019**, *445*, 57–64. [CrossRef]

16. Dreyer, S.B.; Upstill-Goddard, R.; Legrini, A.; Korc, M.; Apte, M.; La Vecchia, C.; Johnson, C.D.; Biankin, A.V.; Neale, R.E.; Tempero, M.; Tuveson, D.A.; Hruban, R.H.; et al. Genomic and Molecular Analyses Identify Molecular Subtypes of Pancreatic Cancer Recurrence. *Gastroenterology 2022*, *162*, 320–324.e324. [CrossRef]

17. Asimgil, H.; Ertetik, U.; Çevik, N.C.; Ekizce, M.; Gökalp, M.; Arık-Sever, E.; Istvanffy, R.; Friess, H.; Ceyhan, G.O.; et al. Targeting the undruggable oncogenic KRAS: The dawn of hope. *JCI Insight 2021*, *6*, e153688. [CrossRef]

18. Saiki, Y.; Jiang, C.; Ohmura, M.; Furukawa, T. Genetic Mutations of Pancreatic Cancer and Genetically Engineered Mouse Models. *Cancers 2021*, *14*, 71. [CrossRef]

19. Ala, M. Target c-Myc to treat pancreatic cancer. *Cancer Biol. Ther.* **2022**, *23*, 34–50. [CrossRef]

20. Kleeff, J.; Korc, M.; Apte, M.; La Vecchia, C.; Johnson, C.D.; Biankin, A.V.; Neale, R.E.; Tempero, M.; Tuveson, D.A.; Hruban, R.H.; et al. Pancreatic cancer. *Nat. Rev. Dis. Primers 2016*, *2*, 16022. [CrossRef]

21. Collisson, E.A.; Bailey, P.; Chang, D.K.; Biankin, A.V. Molecular subtypes of pancreatic cancer. *Nat. Rev. Gastroenterol. Hepatol. 2019*, *16*, 207–220. [CrossRef] [PubMed]

22. Ou, A.; Zhao, X.; Lu, Z. The potential roles of p53 signaling reactivation in pancreatic cancer therapy. *Biochim. Biophys. Acta Rev. Cancer 2022*, *1877*, 188662. [CrossRef] [PubMed]

23. Asghar, U.S.; Kanani, R.; Roylance, S.; Mittnacht, S. Systematic Review of Molecular Biomarkers Predictive of Resistance to CDK4/6 Inhibition in Metastatic Breast Cancer. *JCO Precis. Oncol. 2022*, *6*, e2100002. [CrossRef] [PubMed]

24. Fassl, A.; Geng, Y.; Sicinski, P. CDK4 and CDK6 kinases: From basic science to cancer therapy. *Science 2022*, *375*, eabc1495. [CrossRef]

25. Killock, D. Abemaciclib crowned in monarchE. *Nat. Rev. Clin. Oncol. 2022*, *19*, 5. [CrossRef]

26. Cheng, B.; Pan, W.; Xing, Y.; Xiao, Y.; Chen, J.; Xu, Z. Recent advances in DDR (DNA damage response) inhibitors for cancer therapy. *Eur. J. Med. Chem. 2022*, *230*, 114109. [CrossRef]

27. Prados-Carvajal, R.; Irving, E.; Lukashchuk, N.; Forment, J.V. Preventing and Overcoming Resistance to PARP Inhibitors: A Focus on the Clinical Landscape. *Cancers 2021*, *14*, 44. [CrossRef]

28. Ji, Y.; Liu, X.; Li, J.; Xie, X.; Huang, M.; Jiang, J.; Liao, Y.P.; Donahue, T.; Meng, H. Use of ratiometrically designed nanocarrier targeting CDK4/6 and autophagy pathways for effective pancreatic cancer treatment. *Nat. Commun. 2020*, *11*, 4249. [CrossRef]

29. Wang, S.P.; Li, Y.; Huang, S.H.; Wu, S.Q.; Gao, L.L.; Sun, Q.; Lin, Q.W.; Huang, L.; Meng, L.Q.; Zou, Y.; et al. Discovery of Potent and Novel Dual PARP/BRD4 Inhibitors for Efficient Treatment of Pancreatic Cancer. *J. Med. Chem. 2021*, *64*, 17413–17435. [CrossRef]
30. Majidpoor, J.; Mortezaee, K. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives. *Clin. Immunol.* 2021, 226, 108707. [CrossRef]

31. Torphy, R.J.; Schullik, R.D.; Zhu, Y. Understanding the immune landscape and tumor microenvironment of pancreatic cancer to improve immunotherapy. *Mol. Carcinog.* 2020, 59, 775–782. [CrossRef] [PubMed]

32. Wandmacher, A.M.; Letsch, A.; Sebens, S. Challenges and Future Perspectives of Immunotherapy in Pancreatic Cancer. *Cancers* 2021, 13, 4235. [CrossRef] [PubMed]

33. Saka, D.; Gökalp, M.; Piyaede, B.; Cevik, N.C.; Arik Sever, E.; Unutmaz, D.; Ceyhan, G.O.; Demir, I.E.; Asimgil, H. Mechanisms of T-Cell Exhaustion in Pancreatic Cancer. *Cancers* 2020, 12, 2274. [CrossRef] [PubMed]

34. Ping, Q.; Yan, R.; Cheng, X.; Wang, W.; Zhong, Y.; Hou, Z.; Shi, Y.; Wang, C.; Li, R. Cancer-associated fibroblasts: Overview, progress, challenges, and directions. *Cancer Gene Ther.* 2021, 28, 984–999. [CrossRef] [PubMed]

35. Neesse, A.; Bauer, C.A.; Öhlund, D.; Lauth, M.; Buchholz, M.; Michl, P.; Tuveson, D.A.; Gress, T.M. Stromal biology and therapy in pancreatic cancer: Ready for clinical translation? *Gut* 2019, 68, 159–171. [CrossRef] [PubMed]

36. Ohlund, D.; Handly-Santana, A.; Biffi, G.; Elayda, E.; Almeida, A.S.; Ponz-Sarvise, M.; Corbo, V.; Oni, T.E.; Hearn, S.A.; Lee, E.J.; et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. *Theranostics* 2018, 8, 5072–5087. [CrossRef]

37. Elayda, E.; Bolisetty, M.; Courtois, E.T.; Burkhart, R.A.; Teinor, J.A.; Belleau, P.; Biffi, G.; Lucito, M.S.; et al. Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts. *Cancer Discov.* 2019, 9, 1102–1123. [CrossRef]

38. Sun, Q.; Zhang, B.; Hu, Q.; Qin, Y.; Xu, W.; Liu, W.; Xu, J. The impact of cancer-associated fibroblasts on major hallmarks of pancreatic cancer. *J. Exp. Med.* 2017, 214, 579–596. [CrossRef] [PubMed]

39. Dominguez, C.X.; Müller, S.; Keerthivasan, S.; Koeppen, H.; Hung, J.; Gierke, S.; Breart, B.; Foreman, O.; Bainbridge, T.W.; et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. *Cancer Discov.* 2019, 9, 282–301. [CrossRef] [PubMed]

40. Neuzillet, C.; Tijeras-Raballand, A.; Ragulan, C.; CROS, J.; Patil, Y.; Martinet, M.; Erkan, M.; Klee, J.; Wilson, J.; Apte, M.; et al. Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma. *J. Pathol.* 2019, 248, 51–65. [CrossRef]

41. Baker, A.T.; Abuwarwar, M.H.; Poly, L.; Wilkins, S.; Fletcher, A.L. Cancer-Associated Fibroblasts and T Cells: From Mechanisms to Outcomes. *J. Immunol.* 2021, 206, 310–320. [CrossRef]

42. Huang, H.; Breken, R.A. Recent advances in understanding cancer-associated fibroblasts in pancreatic cancer. *Am. J. Physiol. Cell Physiol.* 2020, 319, C233–C243. [CrossRef]

43. Norton, J.; Foster, D.; Chinta, M.; Titan, A.; Longaker, M. Pancreatic Cancer Associated Fibroblasts (CAF): Under-Explored Target for Pancreatic Cancer Treatment. *Cancers* 2020, 12, 1347. [CrossRef]

44. Polani, F.; Grierson, P.M.; Lim, K.H. Stroma-targeting strategies in pancreatic cancer: Past lessons, challenges and prospects. *World J. Gastroenterol.* 2021, 27, 2105–2121. [CrossRef] [PubMed]

45. Özdemir, B.C.; Pentcheva-Hoang, T.; Carstens, J.L.; Zheng, X.; Wu, C.C.; Simpson, T.R.; Laklai, H.; Sugimoto, H.; Kahler, C.; Novitskyy, S.V.; et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. *Cancer Cell* 2014, 25, 719–734. [CrossRef] [PubMed]

46. Rhim, A.D.; Oberstein, P.E.; Thomas, D.H.; Mirek, E.T.; Palermo, C.F.; Sastra, S.A.; Dekleva, E.N.; Saunders, T.; Becerra, C.P.; Tattersall, I.W.; et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. *Cancer Cell* 2014, 25, 735–747. [CrossRef]

47. Steele, N.G.; Biffi, G.; Kemp, S.B.; Zhang, Y.; Drouillard, D.; Syu, L.; Hao, Y.; Oni, T.E.; Brosnan, E.; Elayda, E.; et al. Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer. *Clin. Cancer Res.* 2021, 27, 2023–2037. [CrossRef]
Biomedicines 2022, 10, 926

55. Wang, Y.; Liang, Y.; Xu, H.; Zhang, X.; Mao, T.; Cui, J.; Yao, J.; Wang, Y.; Jiao, F.; Xiao, X.; et al. Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor prognosis but better immunotherapy response. Cell Discov. 2021, 7, 36. [CrossRef] [PubMed]

56.Affo, S.; Nair, A.; Brundu, F.; Ravichandra, A.; Bhattacharjee, S.; Matsuda, M.; Chin, L.; Filliol, A.; Wen, W.; Song, X.; et al. Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations. Cancer Cell 2021, 39, 883. [CrossRef] [PubMed]

57. Strating, E.; Wassenaar, E.; Verhagen, M.; Rauwerdink, P.; van Schelven, S.; de Hingh, I.; Rinkes, I.B.; Boerma, D.; Witkamp, A.; Lacle, M.; et al. Fibroblast activation protein identifies Consensus Molecular Subtype 4 in colorectal cancer and allows its detection by (68)Ga-FAPi-FET imaging. Br. J. Cancer. 2022. [CrossRef]

58. Chen, Z.; Zhou, L.; Liu, L.; Hou, Y.; Xiong, M.; Yang, Y.; Hu, J.; Chen, K. Single-cell RNA sequencing highlights the role of inflammatory cancer-associated fibroblasts in bladder urothelial carcinoma. Nat. Commun. 2020, 11, 5077. [CrossRef]

59. Qi, J.; Sun, H.; Zhang, Y.; Wang, Z.; Xun, Z.; Li, Z.; Ding, X.; Bao, R.; Hong, L.; Jia, W.; et al. Single-cell and spatial analysis reveal interaction of FAP(+) fibroblasts and SPPI(+) macrophages in colorectal cancer. Nat. Commun. 2022, 13, 1742. [CrossRef]

60. Mhaidly, R.; Mehta-Grigoriou, F. Role of cancer-associated fibroblast subpopulations in immune infiltration, as a new means of treatment in cancer. Immunol. Rev. 2021, 302, 259–272. [CrossRef]

61. Ganguly, K.; Shah, A.; Atri, P.; Rauth, S.; Ponnusamy, M.P.; Kumar, S.; Batra, S.K. Chemokine-mucinome interplay in shaping the heterogeneous tumor microenvironment of pancreatic cancer. Semin. Cancer Biol. 2022. [CrossRef] [PubMed]

62. Hosein, A.N.; Brekken, R.A.; Maitra, A. Pancreatic cancer stroma: An update on therapeutic targeting strategies. Nat. Rev. Gastroenterol. Hepatol. 2017, 14, 487–505. [CrossRef] [PubMed]

63. Lee, J.J.; Bernard, V.; Semaan, A.; Monberg, M.E.; Huang, J.; Stephens, B.M.; Lin, D.; Rajapakse, K.I.; Weston, B.R.; Bhutani, M.S.; et al. Elucidation of Tumor-Stromal Heterogeneity and the Ligand-Receptor Interactome by Single-Cell Transcriptomics in Real-world Pancreatic Cancer Biopsies. Clin. Cancer Res. 2021, 27, 5912–5921. [CrossRef] [PubMed]

64. Domem, A.; Quattanness, D.; Zanivan, S.; Deben, C.; Van Audenaerde, J.; Smits, E.; Wouters, A.; Lardon, F.; Roeven, G.; Verhoeven, Y.; et al. Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer. Cancers 2021, 13, 987. [CrossRef]

65. Gorchs, L.; Kaiser, H. Interactions between Cancer-Associated Fibroblasts and T Cells in the Pancreatic Tumor Microenvironment and the Role of Chemokines. Cancers 2021, 13, 2995. [CrossRef] [PubMed]

66. Sahai, E.; Aastaturop, I.; Cukierman, E.; DeNardo, D.G.; Egeblad, M.; Evans, R.M.; Fearon, D.; Greten, F.R.; Hingorani, S.R.; Hunter, T.; et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat. Rev. Cancer 2020, 20, 174–186. [CrossRef]

67. Boyd, L.N.C.; Andini, K.D.; Peters, G.J.; Kazemier, G.; Giovannetti, E. Heterogeneity and plasticity of cancer-associated fibroblasts in the pancreatic tumor microenvironment. Semin. Cancer Biol. 2021. [CrossRef]

68. Geng, X.; Chen, H.; Zhao, L.; Hu, J.; Yang, W.; Li, G.; Cheng, C.; Zhao, Z.; Zhang, T.; Li, L.; et al. Cancer-Associated Fibroblast (CAF) Heterogeneity and Targeting Therapy of CAFs in Pancreatic Cancer. Front. Cell Dev. Biol. 2021, 9, 655152. [CrossRef]

69. Vaish, U.; Jain, T.; Are, A.C.; Dudeja, V. Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma: An Update on Heterogeneity and Therapeutic Targeting. Int. J. Mol. Sci. 2021, 22, 13408. [CrossRef]

70. Van Audenaerde, J.R.M.; Roeven, G.; Darcy, P.K.; Kershaw, M.H.; Peeters, M.; Smits, E.J.; Lardon, F.; Roeven, G.; Verhoeven, Y.; et al. Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer. Cancers 2021, 13, 987. [CrossRef]

71. Yang, J.; Li, Y.; Sun, Z.; Zhan, H. Macrophages in pancreatic cancer: An immunometabolic perspective. Cancer Lett. 2021, 498, 188–200. [CrossRef] [PubMed]

72. Gan, L.L.; Hii, L.W.; Wong, S.F.; Leong, C.O.; Mai, C.W. Molecular Mechanisms and Potential Therapeutic Reversal of Pancreatic Cancer-Induced Immune Evasion. Cancers 2020, 12, 1872. [CrossRef] [PubMed]

73. Pergamo, M.; Miller, G. Myeloid-derived suppressor cells and their role in pancreatic cancer. Cancer Gene Ther. 2017, 24, 100–105. [CrossRef]

74. Vonderheide, R.H.; Bear, A.S. Tumor-Derived Myeloid Cell Chemoattractants and T Cell Exclusion in Pancreatic Cancer. Front. Immunol. 2020, 11, 605619. [CrossRef] [PubMed]

75. Ware, M.B.; El-Rays, B.F.; Lesinski, G.B. Mirage or long-awaited oasis: Reinvigorating T-cell responses in pancreatic cancer. J. Immunother. Cancer. 2020, 8, e011000. [CrossRef] [PubMed]

76. Lankadasari, M.B.; Mukhopadhyay, P.; Mohammed, S.; Harikumar, K.B. TAMing pancreatic cancer: Combat with a double edged sword. Mol. Cancer 2019, 18, 48. [CrossRef] [PubMed]

77. Fincham, R.E.A.; Delvecchio, F.R.; Goulart, M.R.; Yeong, J.P.S.; Kocher, H.M. Natural killer cells in pancreatic cancer stroma. World J. Gastroenterol. 2021, 27, 3483–3501. [CrossRef] [PubMed]

78. Orhan, A.; Vogelsang, R.P.; Andersen, M.B.; Madsen, M.T.; Hölmich, E.R.; Raskov, H.; Gögenur, I. The prognostic value of tumour-infiltrating lymphocytes in pancreatic cancer: A systematic review and meta-analysis. Eur. J. Cancer 2020, 132, 71–84. [CrossRef]

79. Xu, C.; Sui, S.; Shang, Y.; Yu, Z.; Han, J.; Zhang, G.; Ntim, M.; Hu, M.; Gong, P.; Chen, H.; et al. The landscape of immune cell infiltration and its clinical implications of pancreatic ductal adenocarcinoma. J. Adv. Res. 2020, 24, 139–148. [CrossRef]

80. Theocharides, T.C. Mast cells and pancreatic cancer. N. Engl. J. Med. 2008, 358, 1860–1861. [CrossRef]
81. Ma, Y.; Ullrich, S.E. Intratumoral mast cells promote the growth of pancreatic cancer. *Oncoimmunology* **2013**, *2*, e25964. [CrossRef] [PubMed]
82. Longo, V.; Tamma, R.; Brunetti, O.; Pisconti, S.; Gentierro, A.; Silvestris, N.; Ribatti, D. Mast cells and angiogenesis in pancreatic ductal adenocarcinoma. *Clin. Exp. Med.* **2018**, *18*, 319–323. [CrossRef] [PubMed]
83. Mowbray, N.G.; Griffith, D.; Hammad, M.; Shingler, G.; Kambal, A.; Al-Sareih, B. A meta-analysis of the utility of the neutrophil-to-lymphocyte ratio in predicting survival after pancreatic cancer resection. *HPB* **2018**, *20*, 379–384. [CrossRef]
84. Zhou, Y.; Wei, Q.; Fan, J.; Cheng, S.; Ding, W.; Hua, Z. Prognostic role of the neutrophil-to-lymphocyte ratio in predicting survival after pancreatic cancer resection. *Clin. Chim. Acta* **2018**, *479*, 181–189. [CrossRef]
85. Yu, M.; Guan, R.; Hong, W.; Zhou, Y.; Lin, Y.; Jin, H.; Hou, B.; Jian, Z. Prognostic value of tumor-associated macrophages in pancreatic cancer: A meta-analysis containing 8252 patients. *Clin. Immunol. Acta* **2018**, *479*, 181–189. [CrossRef]
86. Dellal, R.M.; Christakos, P.; Lee, K.; Egawa, S.; Son, Y.I.; Lotze, M.T. Paucity of dendritic cells in pancreatic cancer. *Surgery* **2002**, *131*, 135–138. [CrossRef]
87. Bauer, C.; Dauer, M.; Saraj, S.; Schnurr, M.; Bauernfeind, F.; Sterzik, A.; Junkmann, J.; Jakl, V.; Ie, R.; Oduncu, F.; et al. Dendritic cell-based vaccination of patients with advanced pancreatic carcinoma: Results of a pilot study. *Cancer Immunol. Immunother.* **2011**, *60*, 1097–1107. [CrossRef]
88. Ochi, A.; Nguyen, A.H.; Bedrosian, A.S.; Mushlin, H.M.; Zarbakhsh, S.; Barilla, R.; Zambirinis, C.P.; Fallon, N.C.; Rehman, A.; Palyayeva-Gupta, Y.; et al. MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells. *J. Exp. Med.* **2012**, *209*, 1671–1687. [CrossRef]
89. Kobayashi, M.; Shimoda, S.; Nagai, K.; Ogasawara, M.; Takahashi, H.; Abe, H.; Tani, M.; Okamoto, M.; Tsujitani, S.; Yusa, S.; et al. Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving chemotherapy: A multicenter analysis. *Cancer Immunol. Immunother.* **2014**, *63*, 797–806. [CrossRef]
90. Mayanagi, S.; Kitago, M.; Sakuragi, T.; Matsuda, T.; Fujita, T.; Hijichi, H.; Taguchi, J.; Takeuchi, H.; Itano, O.; Aiura, K.; et al. Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer. *Cancer Sci.* **2015**, *106*, 397–406. [CrossRef]
91. Okamoto, M.; Kobayashi, M.; Yonemitsu, Y.; Koido, S.; Homma, S. Dendritic cell-based vaccine for pancreatic cancer in Japan. *World J. Gastrointest. Pharmacol. Ther.* **2016**, *7*, 133–138. [CrossRef] [PubMed]
92. Hegde, S.; Krishnawar, V.E.; Herzog, B.H.; Zuo, C.; Breden, M.A.; Knolhoff, B.L.; Hogg, G.D.; Tang, J.P.; Baer, J.M.; Mpoj, C.; et al. Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer. *Cancer Cell* **2020**, *37*, 289–307.e289. [CrossRef]
93. Shangguan, A.; Shang, N.; Figini, M.; Pan, L.; Yang, J.; Ma, Q.; Hu, S.; Eresen, A.; Sun, C.; Wang, B.; et al. Prophylactic dendritic cell vaccination controls pancreatic cancer growth in a mouse model. *Cytotherapy* **2020**, *22*, 6–15. [CrossRef]
94. Saxena, M.; Bhardwaj, N. Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment. *Trends Cancer* **2018**, *4*, 119–137. [CrossRef]
95. Cui, C.; Lan, P.; Fu, L. The role of myeloid-derived suppressor cells in gastrointestinal cancer. *Cancer Commun.* **2021**, *41*, 442–471. [CrossRef]
96. Groth, C.; Hu, X.; Weber, R.; Fleming, V.; Altevogt, P.; Utikal, J.; Umansky, V. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. *Br. J. Cancer* **2019**, *120*, 16–25. [CrossRef]
97. Trovato, R.; Fiore, A.; Sartori, S.; Canesi, S.; Giugno, R.; Ciacione, L.; Paisa, S.; Salvia, R.; De Sanctis, F.; Poffe, F.; et al. Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3. *J. Immunother. Cancer* **2019**, *7*, 255. [CrossRef] [PubMed]
98. Peng, M.; Zhang, Q.; Liu, Y.; Guo, X.; Ju, J.; Xu, L.; Gao, Y.; Chen, D.; Mu, D.; Zhang, R. Apolipoprotein A-I Mimetic Peptide L-4F Suppresses Granulocytic-Myeloid-Derived Suppressor Cells in Mouse Pancreatic Cancer. *Front. Pharmacol.* **2020**, *11*, 576. [CrossRef] [PubMed]
99. Kramer, E.D.; Abrams, S.I. Granulocytic Myeloid-Derived Suppressor Cells as Negative Regulators of Anticancer Immunity. *Front. Immunol.* **2020**, *11*, 1963. [CrossRef]
100. Krishnamoorthy, M.; Lenehan, J.G.; Burton, J.P.; Maleki Vareki, S. Immunomodulation in Pancreatic Cancer. *Cancers* **2020**, *12*, 3340. [CrossRef]
101. Mucciolo, G.; Curcio, M.; Roux, C.; Li, W.Y.; Capello, M.; Curto, R.; Chiarello, R.; Giordano, D.; Satolli, M.A.; Lawlor, R.; et al. IL17A critically shapes the transcriptional program of fibroblasts in pancreatic cancer and switches on their protumorigenic functions. *Proc. Natl. Acad. Sci. USA* **2021**, *118*, e2020395118. [CrossRef]
102. McAllister, F.; Bailey, J.M.; Alsina, J.; Nirschl, C.J.; Sharma, R.; Fan, H.; Rattigan, Y.; Roesser, J.C.; Lankapalli, R.H.; Zhang, H.; et al. Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. *Cancer Cell* **2014**, *25*, 621–637. [CrossRef]
103. Hamarsheh, S.; Groß, O.; Brummer, T.; Zeiser, R. Immune modulatory effects of oncogenic KRAS in cancer. *Nat. Commun.* **2020**, *11*, 5439. [CrossRef] [PubMed]
104. Yang, X.P.; Ghoreschi, K.; Steward-Tharp, S.M.; Rodriguez-Canales, J.; Zhu, J.; Grainger, J.R.; Hirahara, K.; Sun, H.W.; Wei, L.; Vahedi, G.; et al. Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. *Nat. Immunol.* **2011**, *12*, 247–254. [CrossRef] [PubMed]
105. Park, M.J.; Moon, S.J.; Lee, E.J.; Jung, K.A.; Kim, E.K.; Kim, D.S.; Lee, J.H.; Kwok, S.K.; Min, J.K.; Park, S.H.; et al. IL-1-IL-17 Signaling Axis Contributes to Fibrosis and Inflammation in Two Different Murine Models of Systemic Sclerosis. *Front. Immunol.* 2018, 9, 1611. [CrossRef]

106. Zhang, Y.; Chandra, V.; Riquelme Sanchez, E.; Dutta, P.; Quesada, P.R.; Rakosi, A.; Zoltan, M.; Arora, N.; Baydogan, S.; Horne, W.; et al. Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer. *J. Exp. Med.* 2020, 217, e20190354. [CrossRef]

107. Schiraldi, M.; Raucci, A.; Muñoz, L.M.; Livoti, E.; Celona, B.; Venereau, E.; Apuzzo, T.; De Marchis, F.; Pedotti, M.; Bachi, A.; et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. *Proc. Natl. Acad. Sci. USA* 2013, 110, 20212–20217. [CrossRef]

108. Zhang, Y.; Chandra, V.; Riquelme Sanchez, E.; Dutta, P.; Quesada, P.R.; Rakosi, A.; Zoltan, M.; Arora, N.; Baydogan, S.; Horne, W.; et al. Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer. *J. Exp. Med.* 2020, 217, e20190354. [CrossRef]

109. Zhang, Y.; Lazarus, J.; Steele, N.G.; Yan, W.; Lee, H.J.; Nwosu, Z.C.; Halbrook, C.J.; Menjivar, R.E.; Kemp, S.B.; Sirihorachai, V.R.; et al. Regulatory T-cell Depletion Alters the Tumor Microenvironment and Accelerates Pancreatic Carcinogenesis. *Cancer Discov.* 2020, 10, 422–439. [CrossRef]

110. Feig, C.; Jones, J.O.; Kraman, M.; Wells, R.J.; Deonarine, A.; Chan, D.S.; Connell, C.M.; Roberts, E.W.; Zhao, Q.; Caballero, O.L.; et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. *Proc. Natl. Acad. Sci. USA* 2013, 110, 20212–20217. [CrossRef]

111. Tang, D.; Kang, R.; Cheh, C.W.; Livesey, K.M.; Liang, X.; Schapiro, N.E.; Benschrop, R.; Sparvero, L.J.; Amoscat, A.A.; Tracey, K.J.; et al. HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. *Oncogene* 2010, 29, 5299–5310. [CrossRef] [PubMed]

112. Schiraldi, M.; Raucci, A.; Muñoz, L.M.; Livote, E.; Celona, B.; Venereau, E.; Apuzzo, T.; De Marchis, F.; Pedotti, M.; Bachi, A.; et al. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. *J. Exp. Med.* 2012, 209, 551–563. [CrossRef] [PubMed]

113. Chen, Y.; Kim, J.; Tang, A.; Rudilla, F.; Couillin, I.; Torheim, E.A.; Rosenbaum, P.; Leclerc, C. IL-17 suppresses the therapeutic activity of cancer vaccines through the inhibition of CD8(+) T-cell responses. *Oncoimmunology* 2020, 9, 1758606. [CrossRef] [PubMed]

114. Zhang, A.; Qian, Y.; Ye, Z.; Chen, H.; Xie, H.; Zhou, L.; Shen, Y.; Zheng, S. Cancer-associated fibroblasts promote M2 polarization of macrophages in pancreatic ductal adenocarcinoma. *Cancer Med.* 2017, 6, 463–470. [CrossRef] [PubMed]

115. Allen, J.L.; Cooke, M.E.; Alliston, T. ECM stiffness primes the TGFβ pathway to promote chondrocyte differentiation. *Mol. Biol. Cell* 2012, 23, 3731–3742. [CrossRef]

116. Huber, M.; Brehm, C.U.; Gress, T.M.; Buchholz, M.; Alashkar Alhamwe, B.; von Strandmann, E.P.; Slater, E.P.; Bartsch, J.W.; Bauer, C.; Lauth, M. The Immune Microenvironment in Pancreatic Cancer. *Int. J. Mol. Sci.* 2020, 21, 7307. [CrossRef] [PubMed]

117. Chen, Y.; Zhou, X.; Zhou, W. The Emerging Regulation of VEGFR-2 in Triple-Negative Breast Cancer. 2020, 10, 422–439. [CrossRef] [PubMed]

118. Tirpe, A.; Gulei, D.; Tirpe, G.R.; Nutu, A.; Irimie, A.; Campomenosi, P.; Pop, L.A.; Connell, C.M.; Roberts, E.W.; Zhao, Q.; Caballero, O.L.; et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. *Proc. Natl. Acad. Sci. USA* 2013, 110, 20212–20217. [CrossRef]

119. Zhang, A.; Qian, Y.; Ye, Z.; Chen, H.; Xie, H.; Zhou, L.; Shen, Y.; Zheng, S. Cancer-associated fibroblasts promote M2 polarization of macrophages in pancreatic ductal adenocarcinoma. *Cancer Med.* 2017, 6, 463–470. [CrossRef] [PubMed]

120. Zhou, X.; Liu, Y.; Hu, M.; Wang, M.; Liu, X.; Huang, L. Relaxin gene delivery modulates macrophages to resolve cancer fibrosis and promotes progression of pancreatic cancer. *Cancer Cell* 2021, 39, 548–565. [CrossRef] [PubMed]

121. Kanai, A.J.; Konieczko, E.M.; Bennett, R.G.; Royce, S.G. Relaxin and fibrosis: Emerging targets, challenges, and future directions. *Mol. Cell. Endocrinol.* 2020, 551–563. [CrossRef] [PubMed]

122. Jiang, H.; Hegde, S.; Knolhoff, B.L.; Zhu, Y.; Herndon, J.M.; Hawkins, W.G.; Shapiro, I.M.; Weaver, D.T.; et al. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. *Cancer Discov.* 2017, 7, 118. [CrossRef] [PubMed]

123. Zhou, X.; Liu, Y.; Hu, M.; Wang, M.; Liu, X.; Huang, L. Relaxin gene delivery modulates macrophages to resolve cancer fibrosis and synergizes with immune checkpoint blockade therapy. *Sci. Adv.* 2021, 7, eabb6596. [CrossRef]

124. Ireland, L.; Luckett, T.; Schmid, M.C.; Mielgo, A. Blockade of Stromal Gas6 Alters Cancer Cell Plasticity, Activates NK Cells, and Inhibits Pancreatic Cancer Metastasis. *Front. Immunol.* 2020, 11, 297. [CrossRef] [PubMed]

125. Tanaka, M.; Siemann, D.W. Gas6/Axl Signaling Pathway in the Tumor Immune Microenvironment. *Cancers* 2020, 12, 1850. [CrossRef] [PubMed]

126. Zdżalik-Bielecka, D.; Poświatła, A.; Kozik, K.; Jastrzębski, K.; Schink, K.O.; Brewinska-Olchowik, M.; Piotowa, K.; Stenmark, H.; Miaczyńska, M. The GAS6-AXL signaling pathway triggers actin remodeling that drives membrane ruffling, macropinocytosis, and cancer-cell invasion. *Proc. Natl. Acad. Sci. USA* 2021, 118, e2024596118. [CrossRef] [PubMed]

127. Kamionka, E.M.; Qian, B.; Gross, W.; Bergmann, F.; Hackert, T.; Beretta, C.A.; Dross, N.; Ryschich, E. Collagen Organization Does Not Influence T-Cell Distribution in Stroma of Human Pancreatic Cancer. *Cancers* 2021, 13, 3648. [CrossRef] [PubMed]
128. Lawal, B.; Lin, L.C.; Lee, J.C.; Chen, J.H.; Bekaii-Saab, T.S.; Wu, A.T.H.; Ho, C.L. Multi-Omics Data Analysis of Gene Expressions and Alterations, Cancer-Associated Fibroblast and Inverse Immune Interventions, Reveals the Onco-Immune Prognostic Relevance of STAT3/CDK2/4/6 in Human Malignancies. Cancers 2021, 13, 954. [CrossRef]

129. MacNeil, T.; Vathiotis, I.A.; Shafi, S.; Aung, T.N.; Zugazagoitia, J.; Gruffer, A.M.; Driscoll, K.; Rimm, D.L. Multiplex Quantitative Analysis of Tumor-Infiltrating Lympocytes, Cancer-Associated Fibroblasts, and CD200 in Pancreatic Cancer. Cancers 2021, 13, 5501. [CrossRef]

130. Tahkola, K.; Ahtiainen, M.; Mecklin, J.P.; Kellokumpu, I.; Laukkarinen, J.; Tammi, M.; Tammi, R.; Väyrynen, J.P.; Böhm, J. Stromal hyaluronan accumulation is associated with low immune response and poor prognosis in pancreatic cancer. Sci. Rep. 2021, 11, 12216. [CrossRef]

131. Nizri, E.; Bar-David, S.; Aizic, A.; Sternbach, N.; Lahat, G.; Wolf, I.; Klausner, J. Desmoplasia in Lymph Node Metastasis of Pancreatic Adenocarcinoma Reveals Activation of Cancer-Associated Fibroblasts Pattern and T-helper 2 Immune Cell Infiltration. Pancreas 2019, 48, 367–373. [CrossRef] [PubMed]

132. Sadozai, H.; Acharjee, A.; Eppenberger-Castori, S.; Gloor, B.; Gruber, T.; Schenk, M.; Karamitopoulou, E. Distinct Stromal and Immune Features Collectively Contribute to Long-Term Survival in Pancreatic Cancer. Front. Immunol. 2021, 12, 643529. [CrossRef] [PubMed]

133. Mace, T.A.; Shakya, R.; Pitarresi, J.R.; Swanson, B.; McQuinn, C.W.; Nordquist, E.; Cruz-Monserrate, Z.; Yu, L.; Young, G.; et al. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut 2018, 67, 320–332. [CrossRef] [PubMed]

134. Principe, D.R.; Park, A.; Dorman, M.J.; Kumar, S.; Viswakarma, N.; Rubin, J.; Torres, C.; McKinney, R.; Munshi, H.G.; Gripp, P.J.; et al. TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell-Mediated Regression of Pancreatic Cancer. Mol. Cancer Ther. 2019, 18, 613–620. [CrossRef]

135. Seo, Y.D.; Jiang, X.; Sullivan, K.M.; Jalikis, F.G.; Szyme, K.S.; Abbas, A.; Vignali, M.; Park, J.O.; Daniel, S.K.; Pollack, S.M.; et al. Mobilization of CD8(+) T Cells via CXC4R4 Blockade Facilitates PD-1 Checkpoint Therapy in Human Pancreatic Cancer. Clin. Cancer Res. 2019, 25, 3934–3945. [CrossRef]

136. Bockorny, B.; Semenisty, V.; Macarulla, T.; Borazanci, E.; Wolpin, B.M.; Stemmer, S.M.; Golan, T.; Geva, R.; Borad, M.J.; Pedersen, K.S.; et al. BL-8040, a CXC4R4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: The COMBAT trial. Nat. Med. 2020, 26, 878–885. [CrossRef] [PubMed]

137. Van Audenaerde, J.R.; Marcq, E.; von Scheidt, B.; Davey, A.S.; Aung, T.N.; Zuzagaogstia, J.; Gruffer, A.M.; Driscoll, K.; Rimm, D.L. Multiplex Quantitative Analysis of Tumor-Infiltrating Lympocytes, Cancer-Associated Fibroblasts, and CD200 in Pancreatic Cancer. Cancers 2021, 13, 5501. [CrossRef]

138. Panni, R.Z.; Herndon, J.M.; Zuo, C.; Hegde, S.; Hogg, G.D.; Knolhoff, B.L.; Breden, M.A.; Li, X.; Krisnawan, V.E.; Khan, S.Q.; et al. Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies. Sci. Transl. Med. 2020, 12, eaau9240. [CrossRef]

139. Michaelis, K.A.; Norgard, M.A.; Zhu, X.; Wolpin, B.M.; Stemmer, S.M.; Golan, T.; Geva, R.; Borad, M.J.; Angeles Ramos, D.M.; et al. The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer. CanStem111P trial: A Phase III study of napabucasin plus nab-paclitaxel with gemcitabine. Future Oncol. 2019, 15, 1295–1302. [CrossRef] [PubMed]
